Aarkstore.com announce a new report through its vast collection of market research report :
Global Active Pharmaceutical Ingredient Market (API) Trends, Competitive Landscape And Forecasts (2011-2016)
For some-more information, Great fully visit:
http://www.aarkstore.com/reports/Global-Active-Pharmaceutical-Ingredient-Market-API-Trends-Competitive-Landscape-And-Forecasts-2011-2016--170174.html
The Development in the High Potency Active Pharmaceutical Ingredient (HPAPI) and Biogeneric drugs is boosting the growth of the Active Pharmaceutical Ingredient (API) market. There has been a paradigm shift in the use of innovative drugs to that of low-cost API drugs after the economic recession, thereby causing a positive impact on the overall growth of the API market. In order to keep abreast with this change, API manufacturers are applying various novel technologies to reduce the processing time in order to yield more production.
The report describes the API market according to types of:
API synthesis
Customers
Players
It also discusses about the API market in various geographies, such as, North America, Europe, and Asia.
The report also describes the HPAPI market according to the types of:
API synthesis
Customers
Players
The Active Pharmaceutical Ingredient (API) forms the most vital part of every formulated end product, and is an important part of the whole pharmaceutical industry. The overall API market was valued at $101.08 billion in 2010, and is expected to grow at a CAGR of 7.9% from 2011 to 2016.
There has been an increase in influence of API players from emerging economies such as India and China after the economic recession. The recession restricted the growth of Innovative sector in developed economies such as the U.S and Europe, as the Innovative sector requires huge investments. This has helped fuel the growth of Generics market in Asian countries such as India and China.
The API market is facing a period of unprecedented growth as market dynamics have undergone a major change with the expiration of patents pertaining to global blockbuster drugs in the U.S. The consequences of the economic crisis has hit the Innovative drugs market hard, with less budgets allocated by the major players for the R&D of Innovative drugs. This has led to drying up of pipelines for new drugs, and therefore the market for generic drugs is quickly growing. Thus, the patent expiry factor is slated to drive the API market for the coming years.
European countries such as the U.K., France, and Germany are promoting the use of Generics by providing incentives to the doctors for writing prescriptions relating to generic drugs and also to the pharmacists if they offer the generic equivalent of prescribed drugs. Thus, generic API market is expected to grow till the year 2016 as compared to the Innovative API Market.
The HPAPI market is driving the API market growth globally at a fast rate. As these compounds are extremely effective in the treatment of cancers, respiratory disorders, and hormonal imbalances, the HPAPIs market is mostly driven by the growth in the oncology therapeutics market worldwide. The global HPAPI market is valued at $8,900 million in 2011, growing at a CAGR of 8.3% till 2016.
The HPAPI compounds are highly effective due to the targeted therapy. Hence, its application for cancers is a major driver. The market of North America is the largest and accounts for major share; followed by Europe; but Asia is growing at a higher CAGR as compared to North America & Europe. The major players for the HPAPI market are SAFC, Novasep, Lonza, Boehringer Ingelheim, and Carbogen Amics.
Mergers and collaborations are the strategies that have been noticed across the API industry. Newer market entrants are causing threats to the existing small and medium manufactures, leading to high competition. To overcome these challenges, companies are now forming joint ventures for sharing the technology to manufacture API drugs. The key to survive in the market for SMEs is joint ventures.
Table of Contents :
1 Introduction
1.1 Key Take-aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Assumptions
1.5.3 Research Methodology For Hpapi Market
2 Summary
3 Market Overview
3.1 Introduction
3.2 Market Structure
3.2.1 Drivers
3.2.1.1 Asia Leading The Global Api Market Participation
3.2.1.2 Major Drugs Approaching Patent Expiries: Spike In The Growth Of Api Market
3.2.1.3 Government Promoting Generic Drug Usage
3.2.2 Restraints
3.2.2.1 Decline In The Overall R&D Expenditure Affecting The Pharmaceutical Industry
3.2.2.2 Big Pharmaceutical Players Shifting Their Focus To Generics: Leading To Increase In Market Fragmentation
3.2.3 Opportunities
3.2.3.1 Shifting Focus To Hpapi
3.2.3.2 Investment Into Biosimilars
3.3 Technology Trends
3.3.1 Continuous Processing Technology
3.3.2 Separation Technology
3.3.2.1 Fermentation Process
3.3.2.2 Purification Process
3.3.2.3 Filtration Process
3.3.2.4 Drying Process
3.3.3 Micro Reactor Technology
3.3.4 Benefits From Micro Reactor Technology & Flow Chemistry
3.3.5 Green Chemistry Manufacturing
3.4 Winning Imperatives
3.4.1.1 Embarking On Advanced Technology
3.4.1.2 Joint Ventures Of Api Manufacturers.
3.4.1.3 Approvals Of Dmfs
3.4.1.4 Tracking Of The Off-patents
3.5 Burning Issues
3.5.1.1 Lack Of Quality Standards
3.5.1.2 Regulatory Affairs
3.5.1.3 Ip Protection To The Asian Market
3.5.1.4 Product Differentiation A Major Concern Of Api Manufacturers.
3.6 Key Market Dynamics
3.7 Market Attractivess
3.7.1 Global Api Market
4 Api Market, By Type Of Synthesis
4.1 Overview
4.2 Sub-segments Of Api Market, By Type Of Synthesis
4.2.1 Synthetic Chemicals Api
4.2.1.1 Synthetic Chemical Apis, By Types
4.2.1.1.1 Innovative
4.2.1.1.2 Generic
4.2.2 Biotech Api
4.2.2.1 By Products
4.2.2.1.1 Monoclonal Antibodies
4.2.2.1.2 Recombinant Proteins
4.2.2.1.3 Vaccines
4.2.2.2 By Customers
4.2.2.2.1 Innovative
4.2.2.2.2 Biogeneric/Biosimilars
5 Api Market, By Players
5.1 Overview
5.2 Captive Api Market
5.3 Merchant Api Market
5.3.1 Merchant Api Market, By Types
5.3.1.1 Innovative
5.3.1.2 Generic
6 Api Market, By Customer Base
6.1 Overview
6.2 Sub-segments Of Api Market, By Customers
6.2.1 Generic Api
6.2.2 Innovative
7 Hpapi Market
7.1 Introduction
7.1.1 Hpapi Classification As Per Safebridge Consultants
7.1.2 Overview: Hpapi Global Market
7.1.3 Manufacturing Capabilities
7.1.3.1 Handling Requirements
7.1.3.2 Personnel Considerations
7.1.3.3 Plant & Equipment
7.1.3.4 Technology
7.2 Hpapi Market, By Products
8 Geographical Analysis
8.1 North America
8.1.1 North America Api Market
8.1.2 North America Hpapi Market
8.1.3 U.S. Api Market
8.1.3.1 Regulatory Approval
8.1.4 U.S. Hpapi Market
8.1.5 Canada Api Market
8.1.5.1 Regulatory Approval
8.1.6 Canada Hpapi Market
8.2 Europe
8.2.1 Europe Api Market
8.2.2 Europe Hpapi Market
8.2.3 U.K. Api Market
8.2.3.1 Regulatory Approval
8.2.4 U.K. Hpapi Market
8.2.5 France Api Market
8.2.5.1 Regulatory Approval
8.2.6 France Hpapi Market
8.2.7 Germany Api Market
8.2.7.1 Regulatory Approval
8.2.8 Germany Hpapi Market
8.2.9 Spain Api Market
8.2.9.1 Regulatory Approval
8.2.10 Spain Hpapi Market
8.2.11 Italy Api Market
8.2.11.1 Regulatory Approval
8.2.12 Italy Hpapi Market
8.2.13 Roe Api Market
8.2.14 Roe Hpapi Market
8.3 Asia
8.3.1 Asia Api Market
8.3.2 Asia Hpapi Market
8.3.3 India Api Market
8.3.3.1 Regulatory Approval
8.3.4 India Hpapi Market
8.3.5 Japan Api Market
8.3.5.1 Regulatory Approval
8.3.6 Japan Hpapi Market
8.3.7 South Korea Api Market
8.3.7.1 Regulatory Approval
8.3.8 South Korea Hpapi Market
8.3.9 China Api Market
8.3.9.1 Regulatory Approval
8.3.10 China Hpapi Market
8.3.11 Roa Api Market
8.3.12 Roa Hpapi Market
9 Competitive Landscape
9.1 Introduction
9.2 Competitive Developments
10 Company Profiles
10.1 Albemarle Corporation
10.1.1 Overview
10.1.2 Financials
10.1.3 Products & Services
10.1.4 Strategy
10.1.5 Developments
10.2 Asymchem Laboratories Inc
10.2.1 Overview
10.2.2 Financials
10.2.3 Products & Services
10.2.4 Strategy
10.2.5 Developments
10.3 Boehringer Ingelheim Gmbh
10.3.1 Overview
10.3.2 Financials
10.3.3 Products & Services
10.3.4 Strategy
10.3.5 Developments
10.4 Cambrex Corporation
10.4.1 Overview
10.4.2 Financials
10.4.3 Products & Services
10.4.4 Strategy
10.4.5 Developments
10.5 Covidien Plc
10.5.1 Overview
10.5.2 Financials
10.5.3 Products & Services
10.5.4 Strategy
10.5.5 Development
10.6 Dr. Reddy's Laboratories Limited
10.6.1 Overview
10.6.2 Financials
10.6.3 Products & Services
10.6.4 Strategy
10.6.5 Developments
10.7 Basf Se
10.7.1 Overview
10.7.2 Financials
10.7.3 Products & Services
10.7.4 Strategy
10.7.5 Developments
10.8 Hospira Inc.
10.8.1 Overview
10.8.2 Financials
10.8.3 Products & Services
10.8.4 Strategy
10.8.5 Developments
10.9 Lonza Group Ag
10.9.1 Overview
10.9.2 Financials
10.9.3 Products & Services
10.9.4 Strategy
10.9.5 Developments
10.1 Matrix Laboratories Limited
10.10.1 Overview
10.10.2 Financials
10.10.3 Products & Services
10.10.4 Strategy
10.10.5 Development
10.11 Mylan Inc
10.11.1 Overview
10.11.2 Financials
10.11.3 Products & Services
10.11.4 Strategy
10.11.5 Developments
10.12 Novartis International Ag
10.12.1 Overview
10.12.2 Financials
10.12.3 Products & Services
10.12.4 Strategy
10.12.5 Developments
10.13 Groupe Novasep
10.13.1 Overview
10.13.2 Financials
10.13.3 Products & Services
10.13.4 Strategy
10.13.5 Developments
10.14 Pfizer Centresource
10.14.1 Overview
10.14.2 Financials
10.14.3 Products & Services
10.14.4 Strategy
10.14.5 Developments
10.15 Ranbaxy Laboratories Limited
10.15.1 Overview
10.15.2 Financials
10.15.3 Products & Services
10.15.4 Strategy
10.15.5 Developments
10.16 Royal Dsm N.V.
10.16.1 Overview
10.16.2 Financials
10.16.3 Products & Services
10.16.4 Strategy
10.16.5 Developments
10.17 Sigma-aldrich
10.17.1 Overview
10.17.2 Financials
10.17.3 Products & Services
10.17.4 Strategy
10.17.5 Developments
10.18 Teva Pharmaceutical Industries Limited
10.18.1 Overview
10.18.2 Financials
10.18.3 Products & Services
10.18.4 Strategy
10.18.5 Developments
10.19 Watson Pharmaceuticals Inc
10.19.1 Overview
10.19.2 Financials
10.19.3 Products & Services
10.19.4 Strategy
10.19.5 Developments
10.2 Wuxi Apptec Co. Ltd.
10.20.1 Overview
10.20.2 Financials
10.20.3 Products & Services
10.20.4 Strategy
10.20.5 Developments
10.21 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.21.1 Overview
10.21.2 Financials
10.21.3 Products & Services
10.21.4 Strategy
10.21.5 Developments
